153 related articles for article (PubMed ID: 8471420)
1. The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo.
Philip PA; Kaklamanis L; Carmichael J; Tonkin K; Morrison H; Gatter K; Harris AL
Br J Cancer; 1993 Apr; 67(4):644-9. PubMed ID: 8471420
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
Vokes EE; Dolan ME; Krishnasamy S; Mick R; Ratain MJ; Berezin F; Brachman D; Whitman G; Schilsky RL; Charette J
Ann Oncol; 1993 Aug; 4(7):591-5. PubMed ID: 8395874
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
4. Selective uptake of toxic nucleoside (125IUdR) by resistant cancer.
Bagshawe KD; Sharma K; Southall PJ; Boden JA; Boxer GM; Patridge TA; Antoniw P; Pedley RB
Br J Radiol; 1991 Jan; 64(757):37-44. PubMed ID: 1998836
[TBL] [Abstract][Full Text] [Related]
5. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
Kinsella TJ; Kunugi KA; Vielhuber KA; McCulloch W; Liu SH; Cheng YC
Cancer Res; 1994 May; 54(10):2695-700. PubMed ID: 8168099
[TBL] [Abstract][Full Text] [Related]
6. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
Kinsella TJ; Schupp JE; Davis TW; Berry SE; Hwang HS; Warren K; Balis F; Barnett J; Sands H
Clin Cancer Res; 2000 Sep; 6(9):3670-9. PubMed ID: 10999760
[TBL] [Abstract][Full Text] [Related]
7. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
8. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.
Harrington KJ; Syrigos KN; Uster PS; Zetter A; Lewanski CR; Gullick WJ; Vile RG; Stewart JS
Br J Cancer; 2004 Jul; 91(2):366-73. PubMed ID: 15199395
[TBL] [Abstract][Full Text] [Related]
9. 5-[123I/125I]iodo-2'-deoxyuridine in metastatic lung cancer: radiopharmaceutical formulation affects targeting.
Semnani ES; Wang K; Adelstein SJ; Kassis AI
J Nucl Med; 2005 May; 46(5):800-6. PubMed ID: 15872354
[TBL] [Abstract][Full Text] [Related]
10. [Influence of hydroxyurea on DNA synthesis of human bone marrow in vivo (author's transl)].
Hartenstein R; Ertl E; Possinger K; Ehrhart H
Klin Wochenschr; 1979 Nov; 57(21):1191-3. PubMed ID: 513612
[TBL] [Abstract][Full Text] [Related]
11. Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver.
Macapinlac HA; Kemeny N; Daghighian F; Finn R; Zhang J; Humm J; Squire O; Larson SM
J Nucl Med; 1996 Apr; 37(4 Suppl):25S-29S. PubMed ID: 8676200
[TBL] [Abstract][Full Text] [Related]
12. Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2'- deoxyuridine after intravesical infusion in patients with bladder cancer.
Mariani G; Collecchi P; Baldassarri S; Di Luca L; Buralli S; Fontanini G; Baranowska-Kortylewicz J; Adelstein SJ; Kassis AI
J Nucl Med; 1996 Apr; 37(4 Suppl):16S-19S. PubMed ID: 8676197
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of high-dose hydroxyurea in lung cancer.
Veale D; Cantwell BM; Kerr N; Upfold A; Harris AL
Cancer Chemother Pharmacol; 1988; 21(1):53-6. PubMed ID: 3342464
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.
Kassis AI; Adelstein SJ; Mariani G
Q J Nucl Med; 1996 Sep; 40(3):301-19. PubMed ID: 8961807
[TBL] [Abstract][Full Text] [Related]
15. Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.
Mariani G; Di Sacco S; Bonini R; Di Luca L; Buralli S; Bonora D; Ricci S; Baranowska-Kortylewicz J; Adelstein SJ; Falcone A; Kassis AI
Acta Oncol; 1996; 35(7):941-5. PubMed ID: 9004775
[TBL] [Abstract][Full Text] [Related]
16. Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver.
Zager JS; Delman KA; Ebright MI; Malhotra S; Larson S; Fong Y
Br J Surg; 2003 Oct; 90(10):1225-31. PubMed ID: 14515291
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin.
Garcia AA; Muggia FM; Spears CP; Jeffers S; Silberman H; Pujari M; Koda RT
Anticancer Drugs; 2001 Jul; 12(6):505-11. PubMed ID: 11459996
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters.
Neshasteh-Riz A; Angerson WJ; Reeves JR; Smith G; Rampling R; Mairs RJ
Br J Cancer; 1997; 75(4):493-9. PubMed ID: 9052399
[TBL] [Abstract][Full Text] [Related]
19. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
20. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
